Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies

禽流感引发生物-疫苗股票激增：随着H5N1疫情加剧，值得关注的ETF

Benzinga · 01/08 09:54

The U.S. reported its first human death from the H5 bird flu strain this week, causing a spike in vaccine developer stocks Moderna (NASDAQ:MRNA), Novavax (NASDAQ:NVAX), CureVac (NASDAQ:CVAC) and Pfizer (NYSE:PFE).

本周，美国报告了首例H5禽流感病毒株的人类死亡案例，这导致了疫苗开发商Moderna（纳斯达克：MRNA）、诺瓦瓦克斯医药（纳斯达克：NVAX）、CureVac（纳斯达克：CVAC）和辉瑞（纽交所：PFE）的股票飙升。

Vaccine production efforts are ramping up as health officials monitor the outbreak closely. In an update on Monday, CDC said there have been 66 confirmed cases in the U.S. in the 2024 outbreak.

随着卫生官员密切关注疫情，疫苗生产工作正在加速。根据周一的更新，CDC表示在2024年的疫情中，美国已有66例确诊病例。

CDC said the public risk remains low. Bird flu has severely impacted poultry farms and cattle herds across 16 states, marking the worst outbreak of its kind.

CDC表示，公众风险仍然较低。禽流感已严重影响到16个州的家禽养殖场和牛群，标志着该类疫情的最严重爆发。

Vaccine Providers in the Limelight

疫苗供应商受到关注

In the...

在美...

登录免费看全文

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies

Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies

风险及免责提示

声明